SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for alleged violations of federal securities laws during the specified Class Period [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Skye securities between November 4, 2024, and October 3, 2025 [2]. - The complaint alleges that Skye's executives made materially false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Skye have until January 16, 2026, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm represents investors on a contingency fee basis, meaning they will only charge fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for recovering hundreds of millions of dollars for investors in securities fraud class actions [6].